Bernzott Capital Advisors Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Bernzott Capital Advisors purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 93,985 shares of the biopharmaceutical company's stock, valued at approximately $4,493,000. Halozyme Therapeutics accounts for about 2.2% of Bernzott Capital Advisors' portfolio, making the stock its 28th largest position. Bernzott Capital Advisors owned about 0.07% of Halozyme Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 350 shares during the period. Skandinaviska Enskilda Banken AB publ purchased a new position in Halozyme Therapeutics in the 2nd quarter valued at about $49,000. Toth Financial Advisory Corp acquired a new stake in Halozyme Therapeutics during the 3rd quarter valued at approximately $57,000. FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $65,000. Finally, Park Place Capital Corp boosted its stake in shares of Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company's stock valued at $78,000 after buying an additional 1,209 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on HALO shares. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $60.89.

Halozyme Therapeutics Trading Down 1.0 %

Halozyme Therapeutics stock traded down $0.57 during trading hours on Friday, reaching $54.80. 942,028 shares of the company's stock traded hands, compared to its average volume of 1,686,593. The firm's 50 day moving average is $49.75 and its 200-day moving average is $54.07. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares of the company's stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.70% of the stock is currently owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.